Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Gavila, Joaquín; Oliveira, Mafalda; Pascual, Tomas; Pérez-García, José; González, Xavier; Canes, Jordi; Pare, Laia; Calvo, Isabel; Ciruelos, Eva; Muñoz, Montserrat; Virizuela, Juan-A; Ruiz, Isabel; Andrés, Raquel; Perello, Antonia; Martínez-García, Jerónimo; Morales, Serafin; Marín-Aguilera, Mercedes; Martínez, Debora; Quero, Juan-C; Llombart-Cussac, Antonio; Prat, Aleix

RICSMUR Principal
→
02. Servicio Murciano de Salud (SMS)
→
02.01. Área de Salud I Murcia Oeste
→
02.01.01. Investigación y comunicación científica
→
Ver ítem

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Gavila, Joaquín; Oliveira, Mafalda; Pascual, Tomas; Pérez-García, José; González, Xavier; Canes, Jordi; Pare, Laia; Calvo, Isabel; Ciruelos, Eva; Muñoz, Montserrat; Virizuela, Juan-A; Ruiz, Isabel; Andrés, Raquel; Perello, Antonia; Martínez-García, Jerónimo; Morales, Serafin; Marín-Aguilera, Mercedes; Martínez, Debora; Quero, Juan-C; Llombart-Cussac, Antonio; Prat, Aleix

URI: https://sms.carm.es/ricsmur/handle/123456789/23674

Fecha: 2019-01-09

Mostrar el registro completo del ítem